Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells-Reference-Cited by-同舟云学术

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells

Published:2017-12-07 Issue:3 Volume:67 Page:483-494
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Bachanova Veronika^ORCID,Sarhan Dhifaf,DeFor Todd E.,Cooley Sarah,Panoskaltsis-Mortari Angela,Blazar Bruce R.,Curtsinger Julie M.,Burns Linda,Weisdorf Daniel J.,Miller Jeffrey S.

Funder

National Institutes of Health

National Center for Advancing Translational Sciences

National Cancer Institute

American Society of Hematology

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-017-2100-1/fulltext.html

Reference35 articles.

1. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag V, Duhrsen U, Ma D, Briere J, Thieblemont C, Bachy E, Moskowitz CH, Glass B, Gisselbrecht C (2017) Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant 52(2):216–221. https://doi.org/10.1038/bmt.2016.213https://doi.org/

2. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA (2015) Chemotherapy-refractory diffuse large B-Cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540–549. https://doi.org/10.1200/JCO.2014.56.2025

3. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O’Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K (2016) Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101(5):531–540. https://doi.org/10.3324/haematol.2015.139493

4. Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13):2286–2294. https://doi.org/10.1182/blood-2010-02-271874

5. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS (2010) Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59(11):1739–1744. https://doi.org/10.1007/s00262-010-0896-z

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives;International Immunopharmacology;2024-12

2. Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment;Bioactive Materials;2024-12

3. Novel insights into immune cells modulation of tumor resistance;Critical Reviews in Oncology/Hematology;2024-10

4. Reprogramming natural killer cells for cancer therapy;Molecular Therapy;2024-09

5. Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective;Biomarker Research;2024-07-17